Back to top

‘There’s an increasing gulf between the people making decisions and the communities that have to live with those decisions,’ says one leading advocate

Shock waves rippled through the network of U.S. HIV/AIDS service organizations when the Centers for Disease Control and Prevention (CDC) announced in July that it would no longer directly fund nearly 100 community-based organizations (CBOs), as it had for many years, instead shifting funding to state and local health departments, which could decide whether they wanted to pass the money on to CBOs. 

 

As Government Executive, a news website that covers the executive branch of the federal government, reported at the time: “A CDC employee [said] that the agency is reverting back to an old model of awarding federal grants that wasn’t as effective at getting funding to the communities hardest hit by HIV. ‘The result is more overhead cost for the states, which means less money that ultimately ends up with the CBOs for HIV prevention,’ the CDC employee said. ‘A lot of money gets lost going down to the CBOs, and it helped with CDC being able to coordinate directly with them.’”

 

The CDC staffer likely spoke anonymously to Government Executive out of fear that they could get in trouble with the White House, particularly with the Office of Management and Budget (OMB), the agency that handed the directive down to the CDC. Under director Russell Vought, the OMB has sought to invoke the president’s previously little-used “impoundment” powers to unilaterally restrict, freeze or cancel congressionally approved funding for a wide range of social and human services programs. 

 

This shift of funds from community groups to state health departments has dramatically shut out populations most affected by social and health issues from having a role in funding and policy. It continues a trend. Over the past two years or so, the federal government has increasingly excluded communities directly affected by HIV—particularly Black, Latine and LGBTQ+ communities—from key decisions.

 

Other major players in the domestic and global HIV response, including pharmaceutical companies and philanthropic foundations, have distanced themselves as well, either taking their cue from the Trump administration and not wanting to run afoul of the White House. Intentionally or not, they have sidelined community members and organizations when making crucial decisions about funding and programming.

 

“There’s an increasing gulf between the people making decisions and the communities that have to live with those decisions,” said Carl Baloney, Jr., president and CEO of AIDS United, a nonprofit that disburses funds to community groups and advocates for policies aimed at ending the HIV epidemic in the U.S. 

 

Baloney is echoed by longtime Chicago-based HIV prevention activist and independent consultant Jim Pickett. “Community engagement has never been well-funded, and it’s often performative, but now I think there’s much less of it,” Pickett said. “The power center now is Big Pharma, which is our biggest funder of services outside of the government. They’re running everything now.”

 

Advocates say this shift away from community engagement is a betrayal of The Denver Principles, a manifesto written in 1983 by people with AIDS demanding that no decisions regarding HIV/AIDS be made without the inclusion of people living with HIV/AIDS and their closest allies and health and service providers. 

 

“As we’ve seen backlash [from the Trump administration] against conversations on diversity, equity and inclusion [DEI], we’ve also seen less discussion of The Denver Principles and the meaningful involvement of people living with and vulnerable to HIV,” said Jeremiah Johnson, executive director of PrEP4All, which advocates for PrEP (HIV prevention medication) access, and cofounder of the Save HIV Funding Campaign.

 

“There are some exceptions, but the trend overall is worrisome,” he said, in that it seems community members are no longer “getting a full picture of what is happening to our communities.”

 

POSITIVELY AWARE spoke with these and about nine other advocates who described a shifting landscape of decision-making. Some spoke with PA anonymously or declined to name individual actors for fear of losing further resources from the government and other funders. 

 

“All of our organizations get money from pharma,” said one advocate. “We all suck from that teat. We’re collectively bought out by them.”

 

All the advocates said that the most vulnerable communities will eventually be hurt by the sidelining. “The progress we’ve made all these decades has been due to strong public engagement of folks that are impacted,” said Baloney. “This is about not using those traditional avenues but instead centralizing power.”

 

The funding shift from community groups to health departments

 

For years, the CDC gave grants directly to hundreds of CBOs across the country. The reason for that, explained Baloney, is that “CBOs have deep relationships with the communities they’re in and the cultural knowledge to know how to reach them.” 

 

But the recent shift to state and local health departments, which can pass some of that money on to organizations of their own choosing, means that at least some groups will go out of business. 

 

One such program, Powerhouse 2.0 in Charlotte, North Carolina, which conducted HIV testing, has apparently already closed. The head of the program’s parent group told The Charlotte Post, a local Black newspaper: “There’s always been a stigma when it comes to HIV testing.... Discretion has always been one of the things when it comes to getting testing, so to be able to pull up to a safe haven, get tested, be able to walk back out and kind of go back to their lives or whatever, that’s a huge plus.... Our local health department doesn’t have the capacity to even test as well.”

 

One national advocate said of the funding shift, “We still have some core folks at CDC we can talk to about this, but they’re not on the inside” of the current administration. “It feels like a lot of the major decisions being made are straight out of OMB, not by folks who have experience” with HIV communities.

 

Ernest Hopkins, senior strategist and advisor at San Francisco AIDS Foundation, said the shift is likely welcomed by both some folks at the CDC who “never wanted to manage all those directly-funded contracts” and by some state and local health departments that “have always bristled at not having control.” 

 

Hopkins added that health departments will be getting far less money than community groups once got, “which will give states maximum deniability against accusations that they are discriminating against Black and Latino agencies.” 

 

Other forms of federal distancing 

 

The CDC funding shift is not the only example of the federal government shutting out community groups. “CDC has become far less accessible overall,” said PrEP4All’s Johnson. 

 

Late in the Biden presidency, he said, PrEP4All worked closely with CDC in launching a free-and-easy PrEP-access pilot program in five high-need jurisdictions around the country, meant to test a possible nationwide PrEP program. 

 

“CDC met with us regularly then,” he said, “but since the Trump 2.0 administration came in, those communication channels have all but been shut off. They’re far less responsive than they used to be. Instead, we’ve been trying to work with advocates who are actually in those jurisdictions”—in part, he said, because, now at CDC, “when it comes to HIV prevention, staffers themselves don’t even know what’s going on. There are fiats from OMB that CDC staff don’t even understand.”

 

Similarly, said Lauren Banks, executive director of the National AIDS Housing Coalition, which advocates primarily on behalf of the federal program HOPWA (Housing Opportunities for Persons with AIDS): “It used to feel like we were collaborating with folks at [the Health Resources and Services Administration], CDC and Housing and Urban Development [HUD]”—all federal agencies that play a key role in the national HIV response—“and now it seems like we’re enemies.” 

 

HUD used to publish performance profiles from the Housing Opportunities for Persons with AIDS program (HOPWA) “so that everyone could see how many people they were housing with HOPWA money, how much HOPWA money was spent in each state,” Banks said. “We could see the states that were under-using their funding, so we could go and advocate with them about what needs to happen.” 

 

She added that HUD would let her group lead a session when it hosted a HOPWA conference.

 

That's all changed, she said. When her group reached out to HUD early in the second Trump administration to try to get a meeting with HUD Secretary Scott Turner, “we were immediately shot down with, ‘Oh, he’s busy.’ We said we were flexible, but all we’ve ever gotten from them is, ‘We’re waiting on leadership to see if we can make this happen’—and then nothing.”

 

In early October, she said, HUD finally issued a call for new applications for HOPWA grants that were supposed to have gone out in July—the delay had left many agencies worrying that they weren’t going to have their HOPWA funding renewed. The delay also meant that many agencies that rely on HOPWA to pay rent for their clients with HIV had to take out loans to cover those costs.

 

The shut-out, Banks said, is different from the situation in the first Trump administration, when then-HUD Secretary Ben Carson met with advocates and even visited some HOPWA sites. 

 

“Grants are supposed to be partnerships between the government and those who carry them out,” she said, whereas now “the government’s lack of communications, the curtness, the delays, the added [hostile] verbiage around harm reduction [such as clean-needle programs for injection drug users] and immigration [such as threats regarding the use of federal programs for undocumented people]—it all adds up to creating a chasm.”

 

Less support from pharma 

 

According to various advocates, leading HIV drugmaker Gilead Sciences, which has long funded HIV community efforts, recently shifted from a relatively straightforward grantmaking process—in which community groups sought funding for projects such as awareness and education events—to a more restrictive system in which the company solicits proposals for initiatives it chooses. 

 

“For years, I relied on this money” from Gilead “for client retreats and information lunches,” said one community group worker who asked to remain anonymous because they did not want to alienate Gilead.

 

“Sometimes it was $5,000, sometimes $10,000, but it was always a big help. Then, I think in 2024, Gilead restructured that whole program. They’d say, ‘Oh, no, we’re not funding that kind of thing anymore.’” Which is a shame, this advocate said, because “this was the alternative to having funding come to us from the CDC or the National Institutes of Health or Ryan White.”

 

Another advocate said of the switch, “I’m guessing Gilead is under a lot of pressure to demonstrate [to investors] impact and return on investment, so they’re doing what they think will get them there.”

 

Asked to confirm this switch and explain when and why it happened, Gilead spokespersons replied via email: “Our commitment to supporting the HIV community has not changed. We continually evaluate how to make the greatest benefit to communities through our investments, with a focus on supporting programs and partnerships that advance HIV prevention, improve access to care and help address health inequities. We remain committed to working alongside community organizations to help meet the evolving needs of people affected by HIV.”

 

The spokespersons declined to confirm the switch as it was characterized by advocates, as well as when it occurred.

 

Hopkins said that Gilead’s switch in how it funds community reflects the drugmaker’s desire to fund large, professional nonprofit health centers with ample insurance billing opportunity—such as Callen-Lorde, a major New York City LGBTQ+ health center—rather than kitchen-table community groups that do community information and awareness events but aren’t large enough to have major reach or provide data quantifying their reach.

 

“The climate [from the Trump administration] has given [drug companies] permission to relook at how they make grants—and so you’re seeing much more investment in organizations with a track record of success. It’s a much less welcoming environment for new players who don’t have a history of service—and historically that has been [groups that serve] communities of color.”

 

He continued: “It used to be sufficient for these little groups to say, ‘We went to a health fair and HIV-tested a certain number of people and gave out a certain number of flyers.’” 

 

No longer, he said. “If the goal is to end the epidemic by keeping people living with HIV virally suppressed and getting as many HIV-negative people as possible on PrEP,” then drug companies likely think it makes “good business sense” to fund Callen-Lorde and other federally qualified health centers (FQHCs).

 

The global freeze-out

 

Powerful governments and other funding entities have pulled back from affected communities not only domestically but globally as well. 

 

The Trump administration has dramatically reduced the scope of PEPFAR, the massive U.S. program funding global HIV prevention and treatment in low-income nations (particularly in Africa), leading to a backslide in progress against HIV/AIDS. 

 

One prominent feature of the cutback has been the elimination of what was once, under former PEPFAR leader Deborah Birx, MD, FACP/FAAM, a regular mechanism for PEPFAR officials and in-country government leadership to receive input from communities most affected, which often include men who have sex with men, sex workers, transgender people, injection-drug users and migrants.

 

Years ago, said Asia Russell, executive director of the global HIV/AIDS advocacy group Health GAP, “activists forced the State Department to make PEPFAR’s planning process. Communities would be part of country operation planning, which is the annual process of developing a workplan, budget and set of targets and goals.” 

 

That participation was not just decorative, she said. Early in PEPFAR’s years in Malawi, affected communities there showed that money PEPFAR spent for costly technical assistance “could be much better spent on real priorities of people with HIV, such as other folks living with HIV trained to be peer community health workers.” 

 

Such community participation continued through Trump’s first term, only to be one of many aspects of PEPFAR destroyed almost immediately in his second term. 

 

Now, the program negotiates one-on-one with recipient countries, largely behind closed doors. “It’s a black box where the Department of State purposely doesn’t include civil society because to do so would undermine the control the U.S. wants to exert over these countries,” said Russell. 

 

That shift away from involving communities is part of a larger effort to conceal PEPFAR’s activities and progress from outside observers and advocates such as himself, said Mitchell Warren, executive director of AVAC, a global HIV prevention advocacy group. 

 

“The U.S. government has dramatically changed how it treats civil society, which has been tumultuous and leaves us with a lot of confusion,” he said.

 

In the past, anyone who wanted to could go to PEPFAR’s online dashboard and see detailed quarterly data about the program’s progress—which Warren and other advocates would do before meeting with PEPFAR leadership. 

 

“We wouldn’t always agree, but at least we were part of the conversation,” he said. “Now, quarter to quarter, we don’t know if we’ll see data or have a conversation about it. There’s not even a clear pathway with whom to talk. It’s almost as if the stage on which it all once happened,” where everyone would meet to talk, “has disappeared.” 

 

This means “we’ve lost the ability to plan” in the long term, he said.

 

What happens next?

 

Despite this trend, advocates said that not all key funders are pulling away from the HIV community. Warren said that organizations including the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Gates Foundation, as well as the governments of other countries, are still willing to engage with community players. 

 

The National AIDS Housing Coalition’s Banks said, “A lot of entities are figuring out how they can help meet the need.” She said that drugmaker ViiV Healthcare and philanthropic funder Broadway Cares/Equity Fights AIDS had both recently given her organization support because they realize the importance of backing advocacy efforts.

 

But as for a reversal of the overall trend away from the community? “The fix would be if Trump 2.0 started wanting to work with us the way they invite the tech bros to the White House,” said Banks, acknowledging that this was unlikely. 

 

She was echoed by Baloney. “It'll take a different administration and a different Congress,” he said—specifically, a Congress willing to pass HIV-related funding with clear language attached that the money is meant to go directly to community groups.

 

But Warren said it’s important for community members and advocates to “play the hand we’ve been dealt right now. Nobody’s waiting to see what happens [with the elections] in November or in 2028. We’re going to have to continue to push this administration for data, and we’re going to have to work around what data don’t exist."

 

Like other advocates interviewed for this story, Warren said the history of the HIV epidemic has shown that the best outcomes are shaped by those closest to and most affected by the crisis.

 

Otherwise, he said, “it’s not like we're totally in the dark—but it’s like trying to fight the virus with one hand tied behind your back.”

 

Responding to an inquiry from Positively Aware, a HUD spokesperson said, “HUD is committed to working with all our grantees.”

OMB and CDC did not respond to emails seeking comment for this story.  g